---
schema_version: "secwatch.filing_event.v1"
accession: "0001380106-25-000050"
form_type: "8-K"
ticker: "RPID"
cik: "0001380106"
company_name: "RAPID MICRO BIOSYSTEMS, INC."
filed_at: "2025-02-28T23:59:59+00:00"
generated_at: "2026-05-25T22:50:54.494460+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rapid Micro Biosystems Q4 revenue $8.2M (+30% YoY); gross margin turns positive; announces MilliporeSigma deal

## Summary
- Q4 2024 revenue $8.2M (up 30% vs $6.3M in Q4 2023); product revenue $5.2M (+27%), service revenue $3.0M (+35%).
- Q4 gross margin 12% (improved from negative 3% in Q4 2023); net loss $9.7M ($0.22 loss per share) vs $11.2M loss.
- FY 2024 revenue $28.1M (+25%); net loss $46.9M ($1.08 per share) improved from $52.5M loss in 2023.
- FY 2025 guidance: total revenue at least $32.0M with 21-25 system placements expected.
- Entered global Distribution & Collaboration Agreement with MilliporeSigma for co-exclusive rights to sell Growth Direct systems and consumables.

## SEC filing metadata
- accession: 0001380106-25-000050
- form_type: 8-K
- ticker: RPID
- cik: 0001380106
- company_name: RAPID MICRO BIOSYSTEMS, INC.
- filed_at: 2025-02-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000050/0001380106-25-000050-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1380106/000138010625000050/rpid-20250228.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001380106-25-000050
- JSON: https://secwatch.observer/filing/0001380106-25-000050.json
- Plain text: https://secwatch.observer/filing/0001380106-25-000050.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.